Positive Update for Vivistim® Procedure Payment
Effective from the start of 2026, the Vivistim® procedure has been assigned to New Technology Ambulatory Payment Classification (APC) 1580. This classification comes with a national average payment of around $45,000 for outpatient procedures. This payment structure recognizes the value and resources required for this innovative treatment, paving the way for its broader adoption.
Significance of Medicare's Decision
MicroTransponder®, Inc., a medical technology innovator, has celebrated the Centers for Medicare and Medicaid Services (CMS)'s assignment of Vivistim to the APC 1580. This decision reflects an understanding of the vital contributions Vivistim makes to stroke recovery. With this new classification, hospitals will be better positioned to offer the therapy, fostering greater access for Medicare beneficiaries.
What is the Vivistim® Paired VNS™ System?
The Vivistim® Paired VNS™ System is a groundbreaking intervention specifically designed to aid chronic stroke survivors. By combining targeted vagus nerve stimulation with goal-oriented activities, the therapy promotes neuroplasticity, encouraging meaningful recovery in upper limb function. This dual approach enhances the overall recovery potential of stroke patients.
Wider Implications for Stroke Care
With the new APC designation, hospitals can now provide Vivistim with adequate reimbursement. This is essential not only for sustainability but also for ensuring that stroke survivors receive the care they need. Richard Foust, President and CEO of MicroTransponder, expressed satisfaction with this development, emphasizing the importance of supporting resources for this crucial therapy.
The Benefits of Vivistim Therapy
Vivistim therapy is a significant advancement in stroke care, aiming to address a critical gap for many stroke survivors seeking rehabilitation. The affordability and accessibility of this treatment will likely improve health outcomes for those covered under Medicare. Furthermore, the positive reception from CMS reinforces the therapy’s role in reshaping stroke recovery protocols nationwide.
About MicroTransponder
MicroTransponder®, Inc. is dedicated to revolutionizing recovery for stroke survivors. Their flagship product, the Vivistim® Paired VNS™ Therapy, is the first FDA-approved technology aimed at enhancing upper limb functionality. This commitment to groundbreaking innovation places MicroTransponder at the forefront of stroke recovery advancements.
Frequently Asked Questions
1. What is the Vivistim® procedure?
The Vivistim procedure is a therapeutic approach designed to improve recovery outcomes for chronic stroke survivors using vagus nerve stimulation.
2. When will the new Medicare payment structure be effective?
The new classification and payment structure will be effective from January 1, 2026.
3. How does the Vivistim therapy work?
Vivistim therapy combines targeted vagus nerve stimulation with specific functional activities to enhance neuroplasticity and motor function in stroke patients.
4. Why is the APC 1580 important?
The APC 1580 classification ensures appropriate reimbursement for the Vivistim procedure, promoting its availability at outpatient settings for stroke survivors.
5. How does MicroTransponder support stroke recovery?
MicroTransponder focuses on developing innovative technologies like the Vivistim system to improve recovery prospects for stroke patients, providing essential resources for rehabilitation.
